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Introduction: Elevated plasma B-type natriuretic peptide (BNP) levels in patients with critical sepsis (severe sepsis
and septic shock) may indicate septic cardiomyopathy. However, multiple heterogeneous conditions may also be
involved in increased BNP level. In addition, the prognostic value of BNP in sepsis remains debatable. In this study,
we sought to discover potential independent determinants of BNP elevation in critical sepsis. The prognostic value
of BNP was also evaluated.
Methods: In this observational study, we enrolled mechanically ventilated, critically septic patients requiring
hemodynamic monitoring through a pulmonary artery catheter. All clinical, laboratory and survival data were
prospectively collected. Plasma BNP concentrations were measured daily for five consecutive days. Septic cardiomyopathy
was assessed on day 1 on the basis of left and right ventricular ejection fractions (EF) derived from echocardiography
and thermodilution, respectively. Mortality was recorded at day 28.
Results: A total of 42 patients with severe sepsis (N = 12) and septic shock (N = 30) were ultimately enrolled. Daily BNP
levels were significantly elevated in septic shock patients compared with those with severe sepsis (P ≤0.002). Critical
illness severity (assessed by Acute Physiology and Chronic Health Evaluation II and maximum Sequential Organ Failure
Assessment scores), and peak noradrenaline dose on day 1 were independent determinants of BNP elevation (P <0.05).
Biventricular EFs were inversely correlated with longitudinal BNP measurements (P <0.05), but not independently.
Pulmonary capillary wedge pressures (PCWP) and volume expansion showed no correlation with BNP. In septic
shock, increased central venous pressure (CVP) and CVP/PCWP ratio were independently associated with early
BNP values (P <0.05).
Twenty-eight-day mortality was 47.6% (20 of 42 patients). Daily BNP values poorly predicted outcome; BNP on
day 1 > 800 pg/ml (the best cutoff point) fairly predicted mortality, with a sensitivity%, specificity% and area under the
curve values of 65, 64 and 0.70, respectively (95% confidence interval = 0.54 to 0.86; P = 0.03). Plasma BNP levels declined
faster in survivors than in nonsurvivors in both critical sepsis and septic shock (P ≤0.002). In septic shock, a BNP/CVP
ratio >126 pg/mmHg/ml on day 2 and inability to reduce BNP <500 pg/ml implied increased mortality (P ≤0.036).
Conclusions: The severity of critical illness, rather than septic cardiomyopathy, is probably the major determinant of
BNP elevation in patients with critical sepsis. Daily BNP values are of limited prognostic value in predicting 28-day
mortality; however, fast BNP decline over time and a decrease in BNP <500 pg/ml may imply a favorable outcome.* Correspondence: y_papanikolaou@hotmail.com
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B-type natriuretic peptide (BNP) is a cardiac hormone
with diuretic, natriuretic and vasorelaxing properties. It
is considered to be produced by ventricular myocardium in
response to increased wall stretch and plays a fundamental
role in regulating cardiac filling pressure and intravascular
volume homeostasis [1-3]. Therefore, BNP is used widely
in cardiology as a valuable biomarker of left ventricular
(LV) dysfunction and increased LV filling pressure [2,4-6].
BNP levels may remain high despite appropriate therapy in
heart failure, however, suggesting that stimuli other than
LV pressure and/or volume overload may be implicated in
the release of the peptide [7].
Plasma BNP concentrations may also be considerably
high in patients with critical sepsis (henceforth, the
term critical sepsis is used to include both severe sepsis
and septic shock) [1,8]. In such patients, BNP has been
proposed as a valuable screening tool to detect underlying
cardiac dysfunction (otherwise known as septic cardiomy-
opathy) [9-11]. Several heterogeneous conditions may also
account for increased BNP levels, such as the intensity
of inflammation per se, vasopressors used, renal failure
and right ventricular (RV) overload [1,8,12-19]. Therefore,
the primary conditions predisposing patients to BNP
elevation in sepsis, as well as the associations between
them, are largely undetermined. In addition, the diagnostic
performance of BNP in predicting sepsis outcomes remains
questionable [9-11,19-21].
In this observational study, we sought potential inde-
pendent determinants of BNP elevation in critical sepsis.
We prospectively evaluated the influence of several clinical
parameters, which have previously been associated with
BNP rise [8-19], on 5-day longitudinal BNP measurements
in critical sepsis patients. These predefined parameters
included (1) LV and RV systolic function; (2) LV and RV
filling pressures and pulmonary artery catheter (PAC)–
derived hemodynamic parameters; (3) sepsis severity
classification systems, which reflect the intensity of systemic
inflammation; (4) renal failure; (5) acute lung injury and
acute respiratory distress syndrome; and (5) iatrogenic
interventions (fluid and vasopressor infusion and venti-
lator settings). In order to provide further insight into
the influence of noradrenaline infusion on BNP rise in
critical sepsis, we also studied BNP levels in patients with
hemorrhagic shock requiring noradrenaline support and
PAC monitoring. Finally, we investigated the diagnostic role
of BNP in predicting mortality in critical sepsis patients.
Methods
In this single-center observational study, we prospectively
examined critically ill patients with severe sepsis and
septic shock admitted to our general ICU during a
3-year period from February 2009 to January 2012.
The inclusion criteria were (1) requirement of supportwith mechanical ventilation and (2) need for hemodynamic
monitoring by using a PAC (with both criteria met for
at least 3 days). Exclusion criteria were (1) younger than
18 years of age; (2) pregnancy; (3) chronic heart disease
(coronary artery disease, cardiac failure, severe valvulopa-
thy and/or cardiomyopathy); (4) chronic renal failure; (5)
known pulmonary hypertension; (6) diseases of the central
nervous system (CNS; for example, meningitis, brain
abscess, cerebral hemorrhage), in which BNP levels are
difficult to interpret [18]; (7) poor echocardiographic
scan quality; and (8) infusion of inotropic agents (dopamine,
dobutamine or levosimendan). Patients receiving noradren-
aline were included in the study.
Preliminary data in three ICU patients with acute blood
loss requiring noradrenaline infusion showed that BNP
concentrations in hemorrhagic shock are extremely lower
than in septic shock patients. Noradrenaline infusion is
considered a potential stimulus for BNP increase [15];
however, its influence on BNP rise in critical sepsis is
undefined. Thus, in order to provide further insight into
the mechanisms involved in BNP production in critical
sepsis, we decided to study BNP kinetics prospectively in
a randomization arm of patients with hemorrhagic shock.
Patients with critical sepsis were managed according
to the standard protocol of care for sepsis [22], including
antibiotics, vasopressors, respiratory support and surgical
intervention if indicated. Clinical management decisions
were made by the attending physicians, including the
intention to place a PAC for diagnosis or monitoring as
part of standard care. All cases were discussed daily in a
multidisciplinary meeting. Deaths that occurred within
28 days after ICU admission were recorded (that is, 28-
day mortality). Patients were considered “survivors” if
they survived for at least 28 days after admission.
The study protocol was approved by the Ethical and
Educational Committee of the University Hospital of
Larissa and conforms to the ethical guidelines of the 1975
Declaration of Helsinki. Patients’ next of kin provided
informed consent for all participants.
Clinical assessment
The patients’ clinical information that we gathered at
baseline included age, sex, reason for admission, mean
arterial blood pressure (mABP, derived from a radial or
femoral artery catheter), heart rate (HR) and arterial
blood gas analysis (pH, partial pressure of oxygen (PaO2)
and partial pressure of carbon dioxide (PaCO2)). Respira-
tory parameters, such as positive end-expiratory pressure
(PEEP) and PaO2/FiO2 ratio (ratio of partial pressure of
oxygen in blood to the oxygen concentration during
mechanical ventilation, as a marker of oxygenation), were
also available at baseline. The Acute Physiology and
Chronic Health Evaluation II (APACHE II) score was used
as a clinical marker of the severity of disease at the time
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renal failure (defined as creatinine level ≥2 mg/dl or
requirement for continuous renal substitution therapy)
were also recorded at least on day 1. The degree of organ
dysfunction or organ failure was quantified by the total max-
imum Sequential Organ Failure Assessment (SOFA) score
[23], defined as the aggregate score of the maximum organ
failure scores calculated for each of the six components
of the SOFA system during the first 5 days of the study.
Pulmonary artery catheterization: hemodynamic
measurements
The PAC catheter (model 93A-431H-7.5F; Baxter Edwards,
Santa Ana, CA, USA), which was equipped with a rapid
response thermistor (response time = 50 ms) for the cal-
culation of right ventricular ejection fraction (RVEF), was
inserted into the jugular or subclavian vein and remained
in place for at least 3 consecutive days. The PAC provided
baseline hemodynamic measurements (day 1) from day 1
to day 3, including mean pulmonary arterial pressure
(mPAP), cardiac index (CI), Systemic Vascular Resistance
Index (SVRI) and pulmonary vascular resistance index
(PVRI), as well as longitudinal assessment of RV and LV
filling pressures (central venous pressure (CVP) and pul-
monary capillary wedge pressure (PCWP), respectively).
Pressure and flow transducers were carefully calibrated
before starting each measurement, as previously described
[24]. Patients were studied while supine, and zero pressure
was measured at atmospheric pressure at the midaxillary
line. All hemodynamic measurements were taken at end
expiration. Criteria for adequate PCWP measurements
were an end-expiratory PCWP less than the end-expiratory
diastolic PAP and a similar increase in both PCWP and
diastolic PAP during inspiration, validating that the
occluded pulmonary artery catheter tip did not reflect
zone 1 or zone 2 conditions. The CVP/PCWP ratio, a
hemodynamic index of RV dysfunction [25], was also
extracted on a daily basis (from day 1 to day 3).
Assessment of left ventricular and right ventricular
systolic function
LV systolic function was assessed by transthoracic echo-
cardiography (Vivid 3 transducer (1.5 to 3.6 MHz); GE
Medical Systems, Milwaukee, WI, USA) within 24 hours
after the induction of critical sepsis. Studies were analyzed
offline by a cardiologist (JP) blinded to patient identity. LV
ejection fraction (LVEF) was calculated from the apical
four-chamber view by using Simpson’s method of disks
and according to recommendations of the American
Society of Echocardiography [26]. RVEF was obtained
by thermodilution (RVEF I computer; Baxter Edwards)
[27] at the same time point as LVEF.
According to a previous classification of LV systolic
function in critical sepsis [28], LVEF was defined asnormal or slightly reduced (LVEF ≥50%), moderately
reduced (LVEF between <50% and ≥35%) and severely
reduced (LVEF <35%). In our mechanically ventilated
patients, PAC-derived RVEF was graded as normal (≥40%),
moderately depressed (≥30% to 39%) or severely depressed
(<30%) as previously described [29].
Radioimmunoassay for B-type natriuretic peptide
measurements
Plasma BNP concentration was measured on a daily basis
from day 1 to day 5 using a Biosite Triage immunoassay
(Biosite Diagnostics, San Diego, CA, USA). During the
first 3 days of the study, blood samples were taken at the
time when hemodynamic measurements were performed.
Statistical analysis
The results are expressed as means ± standard error (SE)
unless otherwise stated. The Kolmogorov-Smirnov test
was used for normality assessment. As appropriate, a χ2
test or Fisher’s exact test was used to compare categorical
variables, and a t-test or Mann-Whitney U test was used
to compare continuous variables. One-way analysis of
variance was used for multiple comparisons. Linear
regression analyses were used to determine associations
among continuous variables. Multivariate linear regression
analysis was used to examine the effect of several uni-
variate predictors in determining BNP measurements
independently. Receiver operating characteristic (ROC)
curve analysis was performed to evaluate the diagnostic
performance of BNP or BNP/CVP ratio in predicting
mortality. To evaluate 5-day BNP kinetics among sub-
groups, mean regression lines were created and com-
pared by using linear mixed model analysis. Univariate
and multivariate (backward stepwise selection method
with probability for the removal of 0.10) logistic regression
analyses were used to determine the association of vari-
ables with 28-day mortality. Kaplan-Meier logrank and
univariate and multivariate (backward stepwise selection
method with probability for removal of 0.10) Cox propor-
tional hazards regression models were used to identify the
strongest predictors of overall time-tagged mortality using
time to death as a continuous variable. Only the variables
with statistically significant associations with mortality
in univariate analysis were included in the multivariate
models. The statistical software package SPSS 17.0 (SPSS,
Chicago, IL, USA) was used.
Results
Forty-two patients with severe sepsis (N = 12) and septic
shock (N = 30) fulfilled the eligibility criteria and were
enrolled in the study. Eleven patients with hemorrhagic
shock were also examined. Differences between groups
according to their baseline clinical characteristics, admit-
ting etiology and outcome are given in Table 1. Additional
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in more detail.
PAC-derived hemodynamic measurements on day 1,
3-day recordings of PCWP and CVP and the incidence
of LV and RV systolic dysfunction at baseline are listed
in Table 2 (for further details see Additional file 1, “The
incidence of LV and RV septic cardiomyopathy” section).Table 1 Clinical characteristics and 28-day mortality in septic
and hemorrhagic shock patients (N = 11)a
Characteristics Septic shock (N = 30) Severe
Age, yr 60.9 ± 1.8 58.8 ± 3
Sex (M/F) 18 (60)/12 (40) 8 (66.7)/
Admitting diagnosis
Medical critical state 21 (70) 8 (66.7)
Surgical critical state 7 (23.3) 3 (25)
Multiple trauma 2 (6.7) 1 (8.3)
Etiology of sepsis
Pneumonia 8 (26.6) 8 (66.7)
Bacteremia/CRS 12 (40) 2 (16.6)
Peritonitis 4 (13.3) 1 (8.3)
Cholecystitis 2 (6.6) 0
Pyelonephritis 1 (3.3) 0
Cellulitis 1 (3.3) 0
Unknown 2 (6.6) 1 (8.3)
Comorbidities in septic patients
Diabetes 6 (20) 3 (25)
Hepatic disease 4 (13.3) 1 (8.3)
Respiratory disease 7 (23.3) 2 (16.6)
Cancer 4 (13.3) 2 (16.6)
Autoimmune disease 5 (16.6) 1 (8.3)
Glucocorticoid therapy 6 (20) 2 (16.6)
Baseline clinical parameters
APACHE II score 19.9 ± 0.8 14.8 ± 0
Peak noradrenaline dose, μg/min 19.7 ± 2.1 –
Fluid balance, ml 5,305.3 ± 218.7 2,802.5 ±
Renal failure 7 (23.3) 4 (33.3)
Baseline ventilatory parameters
pH 7.4 ± 0.01 7.39 ± 0
PEEP, mmHg 5.93 ± 0.13 5.92 ± 0
PaO2/FiO2 ratio 355.9 ± 13.5 341.5 ±
Total maximum SOFA score 10.8 ± 0.4 8.9 ± 0.7
Mortality
28-day mortality 17 (56.67) 3(25)
aANOVA, Analysis of variance; APACHE II, Acute Physiology and Chronic Health Evaluation
pressure of oxygen; PEEP, Positive end-expiratory pressure; Renal failure, Creatinine level
Organ Failure Assessment. bP < 0.05 (septic shock vs. hemorrhagic shock), cP < 0.05 (seve
one-way ANOVA with Bonferroni post hoc test. et-test or χ2 test. Continuous data are presSerial B-type natriuretic peptide measurements and
kinetics in septic shock, severe sepsis and hemorrhagic
shock patients
Longitudinal BNP measurements in septic shock patients
(N = 30), severe sepsis patients (N = 12) and hemorrhagic
shock patients (N = 11) are provided in Table 2. Plasma
BNP levels were drastically elevated in septic shock patientsshock patients (N = 30), severe sepsis patients (N = 12)
sepsis (N = 12) Hemorrhagic shock (N = 11) P-value (ANOVA)
40.2 ± 3.7 <0.001b

















.6 9.8 ± 0.7 <0.001b,c,d
17.8 ± 2.5 0.619e
269.9 3,703.6 ± 398.3 <0.001b,d
0 (0) 0.13
.01 7.41 ± 0.01 0.552
.23 4.82 ± 0.12 <0.001b,c
18.1 368.3 ± 27.9 0.699
8 ± 0.5 0.002b
3 (27.27) 0.085
II; CRS, Catheter-related sepsis; FiO2, Fraction of inspired oxygen; PaO2, Partial
≥2 mg/dl or requirement for continuous renal substitution therapy; SOFA, Sequential
re sepsis vs. hemorrhagic shock) and dP < 0.05 (septic shock vs. severe sepsis), all by
ented as means ± SE, and categorical data are presented as n (%).
Table 2 Echocardiographic, hemodynamic data and serial B-type natriuretic peptide measurements in septic shock
patients (N = 30), severe sepsis patients (N = 12) and hemorrhagic shock patients (N = 11)a
Septic shock (N = 30) Severe sepsis (N = 12) Hemorrhagic shock (N = 11) P-value (one-way ANOVA)
Ventricular systolic function on day 1
LVEF, % 63.97 ± 2.28 60 ± 2.46 72.45 ± 1.67 0.021b
LVEF ≥50% 26 (86.67) 11 (91.67) 10 (90.91) 0.439
LVEF ≥35% to 49% 3 (10) 1 (8.33) 1 (9.09)
LVEF <35% 1 (3.33) 0 0
RVEF, % 32.83 ± 6.52 36.25 ± 1.26 41.73 ± 1.81 <0.001c
RVEF ≥40% 7 (23.33) 2 (16.67) 8 (72.73) 0.004c
RVEF ≥30% to 39% 13 (43.33) 9 (75) 3 (27.27)
RVEF <30% 10 (33.33) 1 (8.33) 0
Baseline hemodynamic measurements
mABP, mmHg 69.5 ± 1.4 74.17 ± 3 75 ± 1.13 0.072
mPAP, mmHg 24.3 ± 0.73 23.33 ± 0.88 19.27 ± 1.48 0.004c
SVI, ml/m2 39.12 ± 1.52 44.44 ± 2.06 31.14 ± 1.18 <0.001b,c
CI, L/min/m2 4.56 ± 0.16 4.37 ± 0.17 3.44 ± 0.13 <0.001b,c
SVRI, dyn/s/cm5/m2 1,078.2 ± 46.1 1,183.1 ± 60.4 1,580.2 ± 64.3 <0.001b,c
PVRI, dyn/s/cm5/m2 221.38 ± 17.3 185.3 ± 24.1 229.03 ± 31.97 0.466
LVSWI, g/m/m2 30.6 ± 1.4 37.1 ± 2.3 27.7 ± 1.1 0.013b,d
Serial PCWP and CVP measurements, mmHg
PCWP (day 1) 12 ± 0.62 13.5 ± 0.64 9.55 ± 0.92 0.013b
PCWP (day 2) 13.8 ± 0.53 13.92 ± 0.54 11.36 ± 0.73 0.027c
PCWP (day 3) 13.5 ± 0.50 14.08 ± 0.48 12.3 ± 0.86 0.222
CVP (day 1) 9.67 ± 0.54 10.25 ± 0.43 7.82 ± 0.58 0.056
CVP (day 2) 9.64 ± 0.42 10.17 ± 0.30 9.35 ± 0.56 0.13
CVP (day 3) 10.73 ± 0.6 10.95 ± 0.57 9.64 ± 0.69 0.464
Serial BNP measurements, pg/ml
BNP (day 1) 1,145.57 ± 101.43 311.33 ± 41.57 56.82 ± 17 0.001c,d
BNP (day 2) 1,232.6 ± 142.37 320.67 ± 39.02 56.4 ± 12.17 0.001b,c,d
BNP (day 3) 1,062.52 ± 136.68 290.75 ± 42.84 74.8 ± 21.1 0.001c,d
BNP (day 4) 944.77 ± 156.01 288.92 ± 54.88 42 ± 13.58 0.002c,d
BNP (day 5) 778.84 ± 145.82 257 ± 64.66 34.17 ± 10.76 0.002c,d
aANOVA, Analysis of variance; BNP, B-natriuretic peptide; CI, Cardiac index; CVP, Central venous pressure; LVEF, Left ventricular ejection fraction; LVSWI, Left Ventricular
Stroke Work Index; mABP, Mean arterial blood pressure; mPAP, Mean pulmonary artery pressure; PCWP, Pulmonary capillary wedge pressure; PVRI, Pulmonary Vascular
Resistance Index; RVEF, Right ventricular ejection fraction; SVI, Stroke volume index; SVRI, Systemic vascular resistance index. bP < 0.05, severe sepsis vs. hemorrhagic
shock; cP < 0.05, septic shock vs. hemorrhagic shock; and dP < 0.05, septic shock vs. severe sepsis (all with Bonferroni post hoc analysis). Continuous data are presented
as means ± SE, and categorical data are expressed as n (%).
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shock patients on any study day (P ≤ 0.002). Five-day BNP
kinetics demonstrated a significantly steeper decline over
time in septic shock patients than in severe sepsis or
hemorrhagic shock patients (Figure 1).
Clinical determinants of B-type natriuretic peptide in critical
sepsis and septic shock
Among several clinical parameters examined in critical
sepsis patients overall (N = 42), APACHE II score, peak
noradrenaline dose, maximum SOFA score [23], LVEF,LV Stroke Work Index (LVSWI) score and RVEF were
found to correlate significantly with serial BNP measure-
ments in univariate linear regression analysis (Table 3).
LV and RV filling pressures (PCWP and CVP, respectively)
were not correlated with their corresponding BNP values
(P > 0.05). Baseline hemodynamic parameters (mABP,
mPAP, CI, SVRI and PVRI), fluid balance, PEEP levels,
PaO2/FiO2 ratio and sepsis-induced renal failure were
not associated with BNP either (P > 0.05).
BNP determinants in univariate analysis were included
in multivariate linear regression models (one model for
Figure 1 Five-day B-type natriuretic peptide kinetics in patients with septic shock (N = 30), severe sepsis (N = 12) and hemorrhagic shock
(N = 11). Circles and vertical lines indicate mean B-type natriuretic peptide (BNP) values and standard deviations (SD), respectively. BNP kinetics are
indicated by the corresponding mean regression lines for septic shock (solid line), severe sepsis (dashed line) and hemorrhagic shock (dotted line).
Septic shock’s mean regression line represents greater mean intercept and steeper mean slope than severe sepsis and hemorrhagic shock regression
lines (1,312.6 vs. 333.5 pg/ml and 74.7 pg/ml, respectively, P < 0.001; and −78.1 pg/ml/day vs. −13.4 and −9.6 pg/ml/day, respectively, P ≤ 0.029).
Intercept of the regression line, BNP value where the regression line crosses the y-axis at theoretical day 0; Slope of the regression line, Rate
at which BNP values change day after day. Black hooks: Bonferroni's subgroup analysis between lines' mean intercepts. Gray hooks: Bonferroni's
subgroup analysis between lines' mean slopes.
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of critical illness, as indicated by APACHE II and max-
imum SOFA scores [23], as well as peak noradrenaline
dose on day 1, showed independent associations with
BNP values. Septic cardiomyopathy, as assessed by LVEF,
LVSWI and RVEF, did not exert any independent effect
on BNP values.
Five-day BNP kinetics according to grading (severity)
scales of peak noradrenaline dose, APACHE II score and
RVEF on day 1 and maximum SOFA score are provided
in Additional file 2. The relationship between the per-
centage daily changes (relative to baseline) in SOFA
scores (indicating the evolution of organ dysfunction)
and BNP levels during the initial 5 days is illustrated in
Additional file 3.
When the analysis was restricted in the subset of septic
shock patients (N = 30), the severity of critical illness
continued to influence BNP levels independently (see
also Additional file 1, “Clinical determinants of BNP in
septic shock” section, and Additional file 4 for further
details). Septic cardiomyopathy was a significant butnot independent determinant of BNP concentrations.
LV filling pressures continued to show no correlation with
corresponding BNP values. Interestingly, CVP on day 1
and CVP/PCWP ratio [25] on day 2 were independently
associated with corresponding BNP values.
Mortality in critical sepsis and septic shock
In the present study, 28-day mortality was 47.6% (20 of 42
patients) in critical sepsis patients overall (N = 42) and
56.7% (17 of 30 patients) in the subset of septic shock
patients (N = 30). The comparisons of patient charac-
teristics according to 28-day survival are presented in
Additional file 5 (for further details, see Additional file 1,
“Determinants of mortality in critical sepsis” section).
Critical illness severity (as indicated by APACHE II and
SOFA scores), peak noradrenaline dose on day 1, higher
BNP levels on day 1 and reduced RVEF were significant
univariate determinants of 28-day mortality. Among these
univariate predictors, peak noradrenaline dose, BNP
and RVEF independently predicted 28-day mortality in
a multivariate Cox regression model. Reduced RVEF
Table 3 Clinical determinants of B-type natriuretic peptide in critical sepsis (N = 42)a
Clinical determinants
of BNP
Univariate linear regression analysis Multivariate linear regression analysis
r R2 P-value β Β (95% CI) P-value
BNP (day 1) APACHE II score 0.553 0.284 <0.001 0.066 9 (−15 to 33) 0.455
SOFA score 0.662 0.438 <0.001 0.176 42.6 (−4 to 90) 0.073
Noradrenaline dose 0.886 0.784 <0.001 0.731 33.4 (23 to 44) <0.001
LVSWI score 0.417 0.174 0.006 −0.003 −0.2 (−12 to 12) 0.968
RVEF −0.490 0.240 0.001 −0.02 −1.9 (−20 to 16) 0.829
BNP (day 2) APACHE II score 0.557 0.310 <0.001 0.154 26.7 (−15 to 69) 0.207
SOFA score 0.639 0.409 <0.001 0.233 72.5 (−9 to 154) 0.080
Noradrenaline dose 0.762 0.58 <0.001 0.502 29.4 (11 to 48) 0.003
LVEF −0.363 0.132 0.009 −0.138 −9.3 (−28 to −9) 0.312
LVSWI score 0.389 0.151 0.011 −0.038 −3.4 (−25 to 18) 0.745
RVEF −0.486 0.236 0.001 0.031 −3.9 (−34 to 42) 0.835
BNP (day 3) APACHE II score 0.645 0.416 <0.001 0.262 40.6 (6 to 75) 0.022
SOFA score 0.708 0.502 <0.001 0.254 68 (0 to 138) 0.05
Noradrenaline dose 0.775 0.601 <0.001 0.430 23.8 (7 to 41) 0.007
LVEF −0.379 0.143 0.009 −0.112 −6.5 (−21 to 8) 0.373
LVSWI score 0.353 0.125 0.027 −0.002 −0.14 (−17 to 17) 0.987
RVEF −0.504 0.254 0.001 −0.031 −3.7 (−35 to 28) 0.815
BNP (day 4) APACHE II score 0.703 0.494 <0.001 0.263 42.4 (0 to 85) 0.05
SOFA score 0.678 0.459 <0.001 0.191 47.6 (−20 to 115) 0.161
Noradrenaline dose 0.801 0.642 <0.001 0.449 24.9 (8 to 42) 0.006
RVEF −0.467 0.218 0.003 −0.133 −15.7 (−41 to 10) 0.223
BNP (day 5) APACHE II score 0.688 0.446 <0.001 0.334 52.9 (7 to 99) 0.025
SOFA score 0.662 0.438 <0.001 0.255 55.6 (−9 to 120) 0.089
Noradrenaline dose 0.720 0.518 <0.001 0.295 15.2 (−2 to 32) 0.083
LVEF −0.363 0.131 0.022 −0.192 −19.4 (−50 to 11) 0.203
RVEF −0.485 0.235 0.003 −0.029 −1.4 (−16 to 13) 0.843
aAPACHE II, Acute Physiology and Chronic Health Evaluation Score II; B,β, Unstandardized and standardized β coefficients, respectively; BNP, B-natriuretic peptide;
CI = Confidence interval; LVEF, Left ventricular ejection fraction; LVSWI, Left Ventricular Stroke Work Index; Noradrenaline dose, Peak noradrenaline dose on day 1;
r = Pearson’s correlation coefficient; R2 = Coefficient of determination; RVEF, Right ventricular ejection fraction; SOFA, Sequential Organ Failure Assessment. Clinical
parameters associated significantly with serial BNP measurements on univariate analysis and independent determinants of BNP on the corresponding multivariate
regression models.
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Cox multivariate survival analysis (Table 4). Additional
file 6 illustrates the Kaplan-Meier 28-day survival curves
of the 42 patients with critical sepsis, stratified according
to BNP, RVEF and peak noradrenaline dose on day 1.
Diagnostic performance of B-type natriuretic peptide in
predicting mortality in critical sepsis and septic shock
In critical sepsis patients, BNP concentrations on day 1
were significantly higher in 28-day nonsurvivors than in
survivors (1,099.5 pg/ml vs. 732.4 pg/ml; P = 0.049); how-
ever, BNP levels showed no significant differences from
day 2 to day 5 (Figure 2, left panel). ROC curve analysis
(Additional file 7) showed that BNP values were of lim-
ited diagnostic accuracy in predicting 28-day mortality.BNP >800 pg/ml on day 1 (the best cutoff point) and >840
pg/ml on day 2 predicted mortality fairly well (sensitivity
(%), specificity (%) and area under the curve (AUC) = 65,
64 and 0.70 (95% confidence interval (CI) = 0.54 to 0.86);
P = 0.03) and sensitivity (%), specificity (%) and AUC = 65,
64 and 0.68 (95% CI = 0.52 to 0.84); P = 0.044) for days 1
and 2, respectively). In the subgroup of septic shock
patients, BNP concentrations did not differ between
nonsurvivors and survivors on any study day (Figure 2,
right panel) and showed no prognostic value in ROC
analysis (Additional file 7). Interestingly, 5-day BNP kinet-
ics presented a significantly steeper decline in survivors
compared to nonsurvivors in critical sepsis patients overall
(P = 0.001) (Figure 2, left panel) and in the subset of septic
shock patients (P = 0.002) (Figure 2, right panel).
Table 4 Cox multivariate survival models examining the effect of univariate determinants and independent predictors
of 28-day mortality in critical sepsis patients (N = 42)a
Hazard ratio 95% CI Wald statistic P-value
Univariate clinical determinants of 28-day mortality
APACHE II score 1.12 0.98 to 1.29 2.75 0.097
Maximum SOFA score 1.13 0.87 to 1.47 0.82 0.366
Peak noradrenaline dose on day 1 1.09 1.01 to 1.17 4.59 0.032
RVEF 0.89 0.8 to 0.99 4.79 0.029
BNP on day 1 0.988 0.996 to 1.000 4.91 0.027
Independent clinical predictors of 28-day mortality
RVEF 0.873 0.78 to 0.97 6.18 0.013
Peak noradrenaline dose on day 1 1.085 1.01 to 1.17 5.11 0.024
BNP on day 1 0.999 0.997 to 1.000 3.16 0.076
aAPACHE II, Acute Physiology and Chronic Health Evaluation II; BNP, B-type natriuretic peptide; CI, Confidence interval; RVEF, Right ventricular ejection fraction;
SOFA score, Total maximum Sequential Organ Failure Assessment score. Among all univariate determinants, RVEF, BNP and peak noradrenaline dose on day 1
independently predicted 28-day mortality. RVEF was the strongest independent predictor among them.
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clinical markers that showed significant prognostic value
for mortality: critical sepsis BNP concentration and BNP/
CVP ratio. Critical BNP concentration was defined as
the lowest 5-day BNP level in each septic shock patient.
Inability to reduce BNP below the critical threshold of
500 pg/ml predicted 28-day mortality with sensitivity (%),
specificity (%) and AUC of 82, 62 and 0.74 (95% CI = 0.55Figure 2 Daily B-type natriuretic peptide measurements and 5-day B-
sepsis (left) and septic shock (right), divided by 28-day mortality. Bars
and standard deviations (SD), respectively. Significant BNP differences on a
are indicated by the corresponding mean regression lines (gray in survivor
mean intercepts, yet significantly steeper mean slopes in survivors than in
septic shock patients (P = 0.002). The intercept of the regression line is the
day 0. The slope of the regression line is the rate at which BNP values chanto 0.93; P = 0.028). In addition, BNP/CVP >126 pg/ml/
mmHg on day 2 predicted mortality with sensitivity (%),
specificity (%) and AUC of 73, 77, 0.73 (95% CI = 0.53 to
0.94; P = 0.036).
Discussion
The main findings of our study are as follows. (1) The se-
verity of critical illness is probably the main determinant oftype natriuretic peptide kinetics in patients with overall critical
and vertical lines indicate mean B-type natriuretic peptide (BNP) values
ny study day (P < 0.05) are marked with asterisks. Five-day BNP kinetics
s and black in nonsurvivors). Mean regression lines represent similar
nonsurvivors, either in overall critical sepsis patients (P = 0.001) or in
BNP value where the regression line crosses the y-axis on theoretical
ge day after day.
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is associated with BNP rise, although not independently,
whereas LV filling pressures do not correlate with the
corresponding BNP concentrations. Noradrenalin dose
may not be a stimulus of BNP secretion per se. (2)
Baseline BNP elevation predicts mortality fairly well;
yet, 5-day BNP kinetics demonstrate a significantly fas-
ter decline over time in survivors than in nonsurvivors.
(3) In the subset of septic shock patients, although BNP
levels were enormously elevated, they had no prognostic
implication. In these patients, an increased BNP/CVP
ratio on day 2 might serve as an early prognostic
marker for mortality, whereas inability to reduce BNP
below the critical threshold of 500 pg/ml may also
imply increased mortality.
In the present study, we found BNP concentrations
to be considerably elevated in septic shock patients
compared with severe sepsis patients on every single
day of assessment (P ≤ 0.002). This finding differs from
the findings of McLean et al. [21], who reported no
escalation of BNP levels from severe sepsis to septic
shock, but it is consistent with the findings in the
studies of Pirracchio et al. [16] and Ueda et al. [30].
As sepsis syndrome evolves and the patient’s condition
continues to deteriorate, several mechanisms may be
involved in BNP elevation, such as proinflammatory
cytokine oversecretion [8,12-14], ensuing systolic and
diastolic biventricular dysfunction [9,10,31], altered
BNP clearance [16], renal failure [32] and sepsis-associated
acute lung injury or acute respiratory distress syndrome
[18]. In addition, several medical interventions employed
with the aim of treating sepsis [22] may trigger BNP release,
such as volume overresuscitation [17,19] and high PEEP
levels (both of which result in RV overload [33]), and
catecholamine infusion [15].
In our series, the severity of sepsis (as indicated by
increased APACHE II and maximum SOFA scores) and
high noradrenaline levels on day 1 were independent
determinants of serial BNP values. In addition, increased
right-side filling pressures (CVP and CVP/PCWP ratio
[25]) were independently associated with early BNP eleva-
tion in the subset of septic shock patients. Sepsis-induced
LV and RV systolic dysfunction, although significantly
associated with serial BNP measurements, were not
independent predictors of BNP elevation. In contrast to
previous data [32], demonstrating a correlation between
BNP and PCWP in critically ill non-cardiac patients
with preserved renal function, but in line with other
previous reports [8,11,34,35], we did not detect any re-
lationship between serial PCWP measurements and the
corresponding BNP values.
Our study provides evidence that it is the severity of
critical illness rather than cardiac dysfunction that ac-
counts for BNP release in the setting of critical sepsis(Table 3 and Additional file 4). In addition, the results of
our study suggest that, in patients with septic shock, RV
overload may play a pivotal role in early BNP rise and
therefore should be carefully evaluated (Additional file 4).
Researchers in previous studies have reported that BNP
can be increased [8,12,14,16] and cardiac contractility may
be depressed [36] secondarily to the activation of several
inflammatory mediators. On this ground, both septic car-
diomyopathy and high BNP levels may be epiphenomena
in severe sepsis patients. Unfortunately, we did not assess
specific inflammatory markers [37] in our study.
Catecholamine oversecretion in critical sepsis patients
may adversely influence cardiac function, coagulation (hy-
percoagulability and thrombus formation), immune system
(immunomodulation and stimulation of bacterial growth)
and metabolism (increase in cellular energy expenditure,
hyperglycemia and impaired glucose tolerance, muscle
catabolism, increased lipolysis and hyperlactatemia). Nor-
adrenaline infusion may further impair organ function
and cardiovascular homeostasis [38]. In an effort to better
comprehend the impact of noradrenaline infusion on BNP
production in septic shock patients, we assessed BNP
concentrations in 11 patients with hemorrhagic shock.
The peak noradrenaline dose was similar between the
two types of shock (Table 1); however, BNP levels were
extremely higher (approximately 20-fold greater) in septic
shock patients than in hemorrhagic shock patients (Table 2
and Figure 1). Our findings suggest that it is neither
noradrenaline infusion per se, as previously suggested
[15], nor the severity of circulatory collapse, but rather
the inflammatory nature of shock that primarily accounts
for BNP elevation in critical sepsis patients [8,12-14].
Furthermore, in our critically septic patients, the level
of vasopressor support was independently associated
with mortality in the Cox proportional hazards analysis
of survival (Table 4). Therefore, we hypothesize that peak
noradrenaline dose on day 1 should be considered as
another marker of the intensity of critical sepsis (along
with the APACHE II and SOFA clinical grading systems,
which were also independent determinants for BNP rise
in this study) rather than an index of circulatory failure or
an independent upregulating factor in BNP rise.
Ueda and co-workers [30], in a study in which they
examined BNP trends in severe sepsis and septic shock
patients, found that the BNP levels peaked on day 2
and decreased gradually afterward. Our data are in line
with these findings; yet, we report greater BNP values
on each study day. In the present study, instead of re-
peated measures of ANOVA [30], we used linear mixed
model analysis to evaluate 5-day BNP kinetics, as the
former has been criticized for producing biased results
due to missing data (deceased patients) during the study
period [39]. We found that BNP kinetics differed signifi-
cantly in the two subgroups of critical sepsis patients, as
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steeper declines in septic shock patients than in severe
sepsis patients (Figure 1). These findings may suggest a
relatively steady state of BNP kinetics over time in severe
sepsis patients, whereas the onset of septic shock is prob-
ably characterized by bursts of BNP secretion.
It has been reported previously that plasma BNP con-
centration on day 2 [10,28,30], on day 3 [9,10] and even
on day 5 [9] predicts mortality in septic shock patients. In
contrast to these results, McLean et al. [21] and Rudiger
et al. [34] failed to demonstrate any predictive utility of
BNP concentration. In a recent meta-analysis [40], Wang
et al. suggested that elevated BNP during the initial 5
days from the onset of critical sepsis may be a powerful
predictor of mortality in septic patients; however, an
ideal cutoff BNP value was not determined. Our data
provide evidence that daily BNP levels are of limited
diagnostic value in predicting 28-day mortality. In critical
sepsis patients, early BNP elevation >800 pg/ml (day 1)
and >840 pg/ml (day 2) may predict mortality and should
be assessed. In the subgroup of septic shock patients,
however, BNP level showed no prognostic value in ROC
analysis (Additional file 7). Instead, 5-day BNP kinetics
demonstrated a significant decline in survivors compared
to nonsurvivors in both critical sepsis and septic shock
patients (Figure 2). A plausible explanation for this
finding is that isolated BNP values are likely to provide
“instant images” of the severity of the disease and can
be affected by several factors in critical illness. How-
ever, persistent elevation of BNP over time may imply
intractable critical illness, despite appropriate thera-
peutic interventions, and, in this respect, it may be of
great prognostic value.
In line with the discussion above, we show that the
daily BNP percentage changes (relative to baseline values)
corresponded well with the evolution of organ dysfunction
assessed by SOFA score percentage alterations from base-
line (Additional file 3). Notably, the 5-day BNP trends
in our septic patients (Figure 2) are comparable to the
previously reported APACHE scores in survivors and
nonsurvivors [36]. These findings may suggest that
the intensity of critical illness is probably the common
denominator of BNP rise and decrease in critical sepsis
patients. Furthermore, our findings provide evidence
that an inability to reduce BNP levels below the critical
threshold of 500 pg/ml may indicate poor outcomes in
septic shock patients. Accordingly, prolonged BNP eleva-
tion should be assessed carefully in critical sepsis patients
because it may imply an untreated underlying pathology,
despite evidence of clinical improvement.
In the present study, we found that a BNP/CVP ra-
tio >126 pg/ml/mmHg, measured on day 2, demonstrated
potential prognostic significance in septic shock patients.
CVP monitoring is the cornerstone for fluid resuscitationin septic shock patients [22]; thus the BNP/CVP ratio is
easy to calculate. The prognostic importance of the BNP/
CVP ratio is that it may provide prognostic information
early in the course of septic shock. Although the greater the
CVP, the higher the BNP values at baseline (Additional
file 4), we found that disproportionately elevated BNP
in relation to CVP after initial fluid resuscitation might
predict increased mortality. Our findings may suggest
that disastrous sepsis, except for increased BNP levels,
is also associated with vascular underfilling, despite
appropriate volume overexpansion [22], possibly due to
extreme systemic vasoplegia and continuing fluid extrava-
sation. It is intriguing to speculate that CVP-guided fluid
resuscitation [22] might have been inadequate in some of
our nonsurvivors; however, whether the BNP/CVP ratio
may be of value in making decisions related to volume
expansion by adding to established clinical data [22] should
be elucidated in future studies.
In our septic patients, we found a greater incidence of
RV than LV systolic dysfunction (Table 2). In addition,
depressed RVEF, but not LVEF, showed an independent
association with mortality (Table 4). However, RVEF and
LVEF were strongly interrelated (Additional file 1), and
both were significantly associated with serial BNP measure-
ments (Table 3). Although mechanical ventilation and/or
hypoxemia may increase PVRI, thus unmasking RV dys-
function, systemic vasoplegia may conceal impaired LV
contractility, resulting in an artificially elevated LVEF [41].
We hypothesized that myocardial depression in sepsis
is global rather than right-sided; however, our findings
suggest that a PAC-derived RVEF may reflect septic
cardiomyopathy better than echocardiography and may
have greater diagnostic and prognostic value in mech-
anically ventilated septic patients.
We acknowledge that there are some points that have
to be considered in the interpretation of our results.
First, 28-day mortality was 56.7% in septic shock patients
and 47.6% in critical sepsis patients. These mortality
rates may be comparable to those reported by previous
researchers who studied similar ICU patient populations
[42,43], but they are higher than currently expected in the
general population of critical sepsis patients [44]. Despite
the fact that direct comparisons with historical studies
are difficult because of differences in study populations
and designs, these differences are likely to be due to the
severity of critical illness and potential comorbidities.
Second, LVEF values may have been affected by changes in
cardiac loading conditions. Certainly, less load-dependent
echocardiographic indices of LV contractility, such as tissue
Doppler imaging–derived mitral annular velocities [45],
might have provided further insight into the role of septic
cardiomyopathy in BNP elevation. However, PAC-derived
LVSWI, which is considered a less load-dependent index
of LV contractility [46], also failed to demonstrate an
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that septic cardiomyopathy is not the major determinant of
BNP rise. Third, dynamic indices of volume responsiveness
(pulse pressure variation and stroke volume variation)
might have identified responders to volume expansion
more precisely than cardiac filling pressures (CVP and
PCWP) [47]. However, CVP-guided fluid resuscitation
was the existing clinical practice at the time our study
was conducted [22]. Fourth, troponin measurements were
not performed systematically in our patients, which is a
potential limitation of our study. Newer, highly sensitive
assays that enable clinicians to identify previously un-
detected pathological troponin levels [48] may provide
more information on the role of myocardial damage in
BNP elevation in septic patients.
Our study has several strengths and originality. We
evaluated cardiac function and hemodynamics as potential
determinants of BNP secretion by using both right heart
catheterization and echocardiography. Moreover, we used
a PAC equipped with a rapid response thermistor for the
assessment of RV systolic function, as echocardiographic
estimation of RV systolic function in mechanically venti-
lated ICU patients is considered problematic in terms of
feasibility and reproducibility [49]. In addition, by compar-
ing septic patients with hemorrhagic shock patients, we
provide evidence that noradrenalin dose may not be a
stimulus of BNP secretion per se.
Conclusions
Our data clearly show that the severity of illness, rather
than sepsis-induced myocardial depression, is the main
determinant of BNP increase in mechanically ventilated
patients with critical sepsis. Increased LV filling pressures
and volume overexpansion during the acute phase of crit-
ical sepsis were not associated with BNP elevation in our
series. Our findings also suggest that increased baseline
BNP values >800 pg/ml and BNP/CVP ratio >126 pg/
mmHg1/ml on day 2 may be early predictors of adverse
outcomes. In addition, prolonged BNP elevation and
inability to reduce BNP below the critical threshold of
500 pg/ml may also imply increased mortality. In this
respect, our study results suggest that both baseline BNP
values and BNP trends should be carefully assessed in the
acute phase of critical sepsis and possibly considered in
the management of the disease.
Key messages
 The severity of critical illness, rather than septic
cardiomyopathy, is probably the main determinant
of BNP rise in critical sepsis patients.
 In septic shock patients, the noradrenalin dose is an
index of critical illness rather than a stimulus for
BNP secretion per se. Daily BNP concentrations are poorly associated with
outcomes; however, early BNP elevation may be of
clinical value in predicting mortality.
 BNP kinetics demonstrate a significantly faster
decline over time in survivors than in nonsurvivors,
in critical sepsis patients overall as well as in the
subset of septic shock patients.
 In the subset of septic shock patients, an increased
BNP/CVP ratio after initial fluid resuscitation and
persistent BNP elevation >500 pg/ml may imply
increased mortality.
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